856 results match your criteria: "Oxford Eye Hospital[Affiliation]"
Eye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Eye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Eye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Eye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Eye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Eye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Eye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Eye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Eye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Ocul Immunol Inflamm
July 2024
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Purpose: We describe a case of vitreous haemorrhage and retinal neovascularization secondary to peripheral retinal ischemia associated with disseminated melanoma.
Methods: A retrospective case report.
Results: A 48-year-old man presented with vitreous haemorrhage in the right eye, peripheral retinal ischemia, and retinal neovascularization in both eyes.
Postgrad Med J
March 2022
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Graefes Arch Clin Exp Ophthalmol
August 2023
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Purpose: To demonstrate different topographic distributions of multiple-evanescent white dot syndrome (MEWDS) and secondary MEWDS disease and to describe possible associations.
Methods: Clinical evaluation and multimodal retinal imaging in 27 subjects with MEWDS (29 discrete episodes of MEWDS). Ophthalmic assessment included best-corrected visual acuity testing and multimodal retinal imaging with OCT, blue-light autofluorescence, fluorescein and indocyanine green angiography, fundus photography, and widefield pseudocolor and autofluorescence fundus imaging.
Vision (Basel)
March 2023
UCL Institute of Ophthalmology, London EC1V 9EL, UK.
Diabetic Retinopathy (DR) is a leading cause of preventable visual impairment in the working age population. Despite the increasing prevalence of DR, there remain gaps in our understanding of its pathophysiology. This is a prospective case-control study comparing the genetic profiles of patients with no DR vs.
View Article and Find Full Text PDFBMJ Open
March 2023
UCL Institute of Ophthalmology, University College London, London, UK
Introduction: Inherited retinal diseases (IRD) are a leading cause of visual impairment and blindness in the working age population. Mutations in over 300 genes have been found to be associated with IRDs and identifying the affected gene in patients by molecular genetic testing is the first step towards effective care and patient management. However, genetic diagnosis is currently slow, expensive and not widely accessible.
View Article and Find Full Text PDFEye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Cochrane Database Syst Rev
March 2023
Genentech Inc, South San Francisco, California, USA.
Background: Acute primary angle closure (APAC) is a potentially blinding condition. It is one of the few ophthalmic emergencies and carries high rates of visual morbidity in the absence of timely intervention. Laser peripheral iridotomy (LPI) has been the standard of care thus far.
View Article and Find Full Text PDFOphthalmol Ther
April 2023
Institut de la Vision, CHNO des Quinze-Vingts, National Rare Disease Center REFERET and INSERM-DGOS CIC 1423, Sorbonne Université, INSERM, CNRS, 75012, Paris, France.
Introduction: Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) are rare inherited retinal degenerative disorders. The Visual Symptom and Impact Outcomes patient-reported outcome (ViSIO-PRO) and observer-reported outcome (ViSIO-ObsRO) instruments were developed in this population to assess visual function symptoms and impacts on vision-dependent activities of daily living (ADL) and distal health-related quality of life (HRQoL). This study aimed to explore the psychometric properties of the ViSIO-PRO and ViSIO-ObsRO in RP/LCA.
View Article and Find Full Text PDFOphthalmol Sci
June 2023
The Lowy Medical Research Institute and the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.
Purpose: To develop a severity classification for macular telangiectasia type 2 (MacTel) disease using multimodal imaging.
Design: An algorithm was used on data from a prospective natural history study of MacTel for classification development.
Subjects: A total of 1733 participants enrolled in an international natural history study of MacTel.
Acta Ophthalmol
September 2023
University Eye Clinic, Maastricht University Medical Center+, Maastricht, the Netherlands.
Purpose: To evaluate the performance of different probabilistic classifiers to predict posterior capsule rupture (PCR) prior to cataract surgery.
Methods: Three probabilistic classifiers were constructed to estimate the probability of PCR: a Bayesian network (BN), logistic regression (LR) model, and multi-layer perceptron (MLP) network. The classifiers were trained on a sample of 2 853 376 surgeries reported to the European Registry of Quality Outcomes for Cataract and Refractive Surgery (EUREQUO) between 2008 and 2018.
Early Hum Dev
March 2023
Research and Evidence Team, Royal College of Paediatrics and Child Health, London, UK.
Cells
January 2023
Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford OX3 9DU, UK.
Inherited retinal diseases (IRD) are a clinically and genetically heterogenous group of diseases and a leading cause of blindness in the working-age population. Even though gene augmentation therapies have shown promising results, they are only feasible to treat a small number of autosomal recessive IRDs, because the size of the gene is limited by the vector used. DNA editing however could potentially correct errors regardless of the overall size of the gene and might also be used to correct dominant mutations.
View Article and Find Full Text PDFJAMA Ophthalmol
March 2023
Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
Importance: X-linked retinitis pigmentosa (XLRP) is a severe cause of early-onset RP in male individuals, characterized by degeneration of photoreceptors, an extinguished electroretinogram, and vision loss.
Objective: To assess the duration of improvements in retinal sensitivity associated with a single, subretinal injection of cotoretigene toliparvovec (BIIB112/AAV8-RPGR) gene therapy after vitrectomy surgery in the dosed eye over 12 months in part 1 of the Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS) study, compared with untreated fellow eyes and eyes from the untreated subgroup from the Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS) study.
Design, Setting, And Participants: This was a post hoc analysis of the XIRIUS and XOLARIS studies.
Transl Vis Sci Technol
February 2023
Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Purpose: The scotopic macular integrity assessment (S-MAIA) can perform scotopic assessment to detect localized changes to scotopic rod and cone function. This study is an exploratory investigation of the feasibility of using the S-MAIA in a rod-cone dystrophy population to identify the pattern of loss in scotopic photoreceptor function.
Methods: Twenty patients diagnosed with a rod-cone dystrophy underwent visual acuity testing, full-field stimulus threshold assessment, and multiple S-MAIA tests after dark adaptation periods of 20 minutes and 45 minutes performed separately.
Eye (Lond)
August 2024
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.